Skip to content
OpenCapital
Get started

Veradermics MANE AFS and Trading Securities - Unrealized Loss Position Fair Value

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K—
Total equity$390.6M+744%
Total assets$397.4M—

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$3.92B—

Returns & leverage

See full
Return on equity-28.7%—
Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's afs and trading securities - unrealized loss position fair value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's AFS and trading securities - unrealized loss position fair value?
Veradermics (MANE) reported AFS and trading securities - unrealized loss position fair value of $267.4M in Q1 2026.